(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 March 2012 (15.03.2012)

PCT

(10) International Publication Number
WO 2012/032031 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/5025 (2006.01)

(21) International Application Number:
PCT/EP2011/065368

(22) International Filing Date:
6 September 2011 (06.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10176134.4	10 September 2010 (10.09.2010)	EP
11075022.1	4 February 2011 (04.02.2011)	EP
11170775.8	21 June 2011 (21.06.2011)	EP
11170771.7	21 June 2011 (21.06.2011)	EP

(71) Applicant *(for all designated States except US)*: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müller Strasse 178, 13353 Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KLAR, Ulrich** [DE/DE]; Isegrimsteig 8a, 13503 Berlin (DE). **KOPPITZ, Marcus** [DE/DE]; Scharnhorststr. 28, 10115 Berlin (DE). **JAUTELAT, Rolf** [DE/DE]; Zur Pumpstation 35, 42781 Haan (DE). **KOSEMUND, Dirk** [DE/DE]; Klutstr. 14, 12587 Berlin (DE). **BOHLMANN, Rolf** [DE/DE]; Kuehler Weg 6a, 14055 Berlin (DE). **LIENAU, Philip** [DE/DE]; Pücklerstr. 33, 10997 Berlin (DE). **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **WENGNER, Antje, Margret** [DE/DE]; Dunckerstr. 7, 10437 Berlin (DE).

(74) Common Representative: **BAYER PHARMA AKTIENGESELLSCHAFT**; Law and Patents, Patents and Licensig, Müller Strasse 178, 13353 Berlin (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: SUBSTITUTED IMIDAZOPYRIDAZINES



(I)

(57) **Abstract**: The present invention relates to substituted imidazopyridazine compounds of general formula (I), which are Mps -1 (Monopolar Spindle 1) Kinase inhibitors (also known as Tyrosine Threonine Kinase, TTK) in which R^3, R^5, and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

WO 2012/032031 A1